These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8057112)

  • 1. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease.
    Planté-Bordeneuve V; Davis MB; Maraganore DM; Marsden CD; Harding AE
    J Neurol Neurosurg Psychiatry; 1994 Aug; 57(8):911-3. PubMed ID: 8057112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy.
    Planté-Bordeneuve V; Bandmann O; Wenning G; Quinn NP; Daniel SE; Harding AE
    Mov Disord; 1995 May; 10(3):277-8. PubMed ID: 7651442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease.
    Smith CA; Gough AC; Leigh PN; Summers BA; Harding AE; Maraganore DM; Sturman SG; Schapira AH; Williams AC
    Lancet; 1992 Jun; 339(8806):1375-7. PubMed ID: 1350805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism.
    Landi MT; Ceroni M; Martignoni E; Bertazzi PA; Caporaso NE; Nappi G
    Adv Neurol; 1996; 69():61-72. PubMed ID: 8615186
    [No Abstract]   [Full Text] [Related]  

  • 5. Mutant debrisoquine hydroxylation genes in Parkinson's disease.
    Armstrong M; Daly AK; Cholerton S; Bateman DN; Idle JR
    Lancet; 1992 Apr; 339(8800):1017-8. PubMed ID: 1349052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease.
    Bordet R; Broly F; Destée A; Libersa C
    Adv Neurol; 1996; 69():97-100. PubMed ID: 8615190
    [No Abstract]   [Full Text] [Related]  

  • 7. Association between the oxidative polymorphism and early onset of Parkinson's disease.
    Agúndez JA; Jiménez-Jiménez FJ; Luengo A; Bernal ML; Molina JA; Ayuso L; Vázquez A; Parra J; Duarte J; Coria F
    Clin Pharmacol Ther; 1995 Mar; 57(3):291-8. PubMed ID: 7697946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2D6 allelic frequencies in young-onset Parkinson's disease.
    Sandy MS; Armstrong M; Tanner CM; Daly AK; Di Monte DA; Langston JW; Idle JR
    Neurology; 1996 Jul; 47(1):225-30. PubMed ID: 8710083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial Parkinson's disease and polymorphism at the CYP2D6 locus.
    Mazzetti P; Le Guern E; Bonnet AM; Vidailhet M; Brice A; Agid Y
    J Neurol Neurosurg Psychiatry; 1994 Jul; 57(7):871-2. PubMed ID: 8021689
    [No Abstract]   [Full Text] [Related]  

  • 10. Debrisoquine hydroxylase gene polymorphism frequencies in patients with amyotrophic lateral sclerosis.
    Siddons MA; Pickering-Brown SM; Mann DM; Owen F; Cooper PN
    Neurosci Lett; 1996 Apr; 208(1):65-8. PubMed ID: 8731176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q13?
    Wilhelmsen K; Mirel D; Marder K; Bernstein M; Naini A; Leal SM; Cote LJ; Tang MX; Freyer G; Graziano J; Mayeux R
    Ann Neurol; 1997 Jun; 41(6):813-7. PubMed ID: 9189044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel cytochrome P-450IID6 mutant gene associated with Parkinson's disease.
    Tsuneoka Y; Matsuo Y; Iwahashi K; Takeuchi H; Ichikawa Y
    J Biochem; 1993 Aug; 114(2):263-6. PubMed ID: 7903297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Debrisoquine hydroxylase gene polymorphism in meningioma.
    Wundrack I; Meese E; Müllenbach R; Blin N
    Acta Neuropathol; 1994; 88(5):472-4. PubMed ID: 7847077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Debrisoquine hydroxylase and Parkinson's disease.
    Kondo I; Kanazawa I
    Adv Neurol; 1993; 60():338-42. PubMed ID: 8420147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians.
    Hadidi HF; Cholerton S; Monkman SC; Armstrong M; Irshaid YM; Rawashdeh NM; Daly AK; Idle JR
    Pharmacogenetics; 1994 Jun; 4(3):159-61. PubMed ID: 7920696
    [No Abstract]   [Full Text] [Related]  

  • 16. CYP2D6 polymorphism and Parkinson's disease susceptibility.
    Sabbagh N; Brice A; Marez D; Dürr A; Legrand M; Lo Guidice JM; Destée A; Agid Y; Broly F
    Mov Disord; 1999 Mar; 14(2):230-6. PubMed ID: 10091614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease.
    Kurth MC; Kurth JH
    Am J Med Genet; 1993 Oct; 48(3):166-8. PubMed ID: 8291573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE; Relling MV
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial NADH dehydrogenase and CYP2D6 genotypes in Lewy-body parkinsonism.
    Kösel S; Lücking CB; Egensperger R; Mehraein P; Graeber MB
    J Neurosci Res; 1996 Apr; 44(2):174-83. PubMed ID: 8723226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic analysis of the CYP2D6 gene in patients with Parkinson's disease.
    Tsuneoka Y; Matsuo Y; Ichikawa Y; Watanabe Y
    Metabolism; 1998 Jan; 47(1):94-6. PubMed ID: 9440484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.